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An important breakthrough in US public
health policy has the potential to accelerate
the development of vaccines to prevent
infectious disease epidemics that currently
kill millions worldwide each year.
Responding to an urgency for new
vaccines for global diseases, in September
2008 the Center for Biologics Evaluation
and Research (CBER) at the US Food and
Drug Administration (FDA) published an
important FDA Guidance Document (see
Box 1), ‘‘General Principles for the
Development of Vaccines to Protect
Against Global Infectious Diseases,’’ [1]
that should expand the FDA’s role in
facilitating the development of new vac-
cines for global bacterial, viral, and
parasitic diseases affecting millions of
people in developing countries worldwide.
In part, this action is in response to a
changing paradigm in advocacy for global
diseases and recognition on the part of
developed nations that the facilitation of
vaccines and other products for neglected
diseases disproportionately affecting those
living in poverty is an effort that benefits
industrialized as well as low-income coun-
tries. Moreover, through the effort of
researchers, the pharmaceutical and bio-
technology industries, and guided by
nongovernmental product development
partnerships, many funded by the Bill &
Melinda Gates Foundation, preventative
vaccines for global diseases are becoming a
reality. Recent progress in this area is
exemplified by both a meningococcal
vaccine [2] and a new malaria vaccine
moving forward into phase III efficacy
trials in several African nations [3] and by
several candidate vaccines for the preven-
tion of tuberculosis being tested in phase I
and II trials [4]. Vaccines and therapeutics
for other viral [5], bacterial [6], and
parasitic [7] neglected diseases are also in
various stages of progress.
As these new products enter into clinical
trials, it has become clear to product
development partners that it is critically
important to identify regulatory pathways
leading to the timely evaluation and
acceptance of safe and effective life-saving
interventions. However, this effort is
impeded by the fact that regulatory
agencies in developing countries where
tropical diseases are endemic often lack
the capacity to review applications for new
vaccines, resulting in lengthy delays in
obtaining permission to conduct clinical
trials. Better-resourced regulatory agencies
such as the US FDA, Health Canada, and
the European Union’s European Medi-
cines Agency (EMEA) have been willing to
help strengthen regulatory authorities in
developing countries, mostly through ca-
pacity-building and training programs
coordinated by the World Health Orga-
nization (WHO), yet their ability to license
new vaccines for global diseases has been
restricted by the paucity of these diseases
within their countries [8]. Some new
approaches are being undertaken by the
EMEA and by WHO and are briefly
described here.
In 2004 the European Union intro-
duced a resolution (Article 58) stating that
the EMEA could provide a scientific
opinion equivalent to a marketing autho-
rization in cooperation with WHO for the
evaluation of medicinal products intended
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Box 1. FDA Guidance Documents
Guidance documents issued by the FDA contain nonbinding recommendations
that represent the agency’s current thinking on a specific topic. This is in contrast
to regulations that appear in the US Code of Federal Regulations, which are
legally binding and enforceable by the FDA. Approaches other than those
discussed in the guidance document can be used by product developers if they
satisfy the requirements of applicable regulations. Guidance documents are
developed by individual Centers at the FDA according to designated
responsibilities; for example, the guidance on vaccines for global diseases
discussed in this report was developed by the Office of Vaccines Research and
Review within CBER/FDA. The most common driving force behind the
development of guidance documents is the identification of gaps or needs in
manufacturing, product characterization, clinical review, and interpretation of
policy that if addressed will facilitate the development of safe and effective
products. Guidance documents are usually issued as draft documents open for
public comment through the US Federal Register via http://www.regulations.gov/.
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The intent of the statute was to provide
sponsors of products for developing coun-
tries the opportunity to use the expert
regulatory review services of the EMEA to
evaluate the purity, safety, and effective-
ness of a new product and to obtain a
‘‘certificate’’ equivalent to a European
marketing license. In addition, Article 58
overcame an EU rule that required the
withdrawal of an EU marketing authori-
zation if the product was not marketed in
Europe for three years. In order to be
eligible for the Article 58 procedure, the
product must be intended to prevent or
treat diseases of major public health
interest as defined by WHO. This list of
target diseases includes major health
threats such as HIV/AIDS, malaria, and
tuberculosis as well as vaccines for possible
use in the Expanded Programme on
Immunization (http://www.wpro.who.
int/sites/epi/) and to stockpile for emer-
gency use. The dossier submitted by the
sponsor for evaluation must be equivalent
to that required for marketing authoriza-
tion. A valid ‘‘scientific opinion’’ resulting
from the review procedure can be used as
a condition for prequalification by WHO
for global distribution of the product (see
below). Since the Article 58 process has
been little used since its inauguration (the
EMEA Web site indicates that three drugs
for HIV/AIDS and one combination
vaccine, Globorix, have been submitted
for consideration; however, the vaccine
was withdrawn by the sponsor prior to the
opinion), questions remain such as: ‘‘What
are the obligations of the manufacturer,
WHO, and developing countries in the
process?’’ and ‘‘Who is responsible for
post-marketing surveillance and pharma-
covigilance once the product is marketed
in a country?’’
The original intent of WHO’s prequal-
ification system established in 1989 was to
assess the acceptability of vaccines for
purchase by United Nations agencies for
global distribution (see [10]). The goal was
to provide the potential for more wide-
spread global immunization with safe and
effective vaccines to prevent the diseases
that occur most frequently worldwide. The
program relies on the ability of the
national regulatory authority of the coun-
try of the product manufacturer to assure
general safety and effectiveness of the
product via its normal approval process.
In addition, the national regulatory au-
thority as well as the manufacturer are
assessed (prequalified) using specific WHO
criteria [11]. Also, distribution lots of
vaccine are randomly check-tested accord-
ing to WHO-specified criteria, surveil-
lance methods are used to monitor
immunized populations for adverse events,
and the product often needs to successfully
meet standards set by a specific WHO
recommendations document. The ‘‘Pre-
qualification’’ program is administered by
the Immunization, Vaccines and Biologi-
cals Department of WHO, and specific
committees play parallel roles in assuring
the quality of the product, such as the
Expert Committee on Biological Stan-
dardization, which develops a specific
recommendations document on the use
of the vaccine, and the Global Advisory
Committee on Vaccine Safety, which
reviews and publishes reports on safety
issues related to specific vaccines. Manu-
facturers apply for prequalification of their
products to meet the needs of a list of
priority products determined by UNICEF,
the Pan American Health Organization,
or recommendations from others such as
the Global Alliance for Vaccines and
Immunization. A licensed vaccine is nor-
mally required to implement the prequal-
ification process, which can result in an
added delay for introducing new vaccines;
however, parallel and fast-track reviews
can be requested for certain products for
high-priority diseases, which can shorten
the timelines of new much-needed vac-
cines. Licensure of a new vaccine for a
global infectious disease via the FDA’s new
licensure process or through the EMEA’s
Scientific Opinion process can be linked to
WHO’s Prequalification program to en-
sure global distribution of the vaccine.
‘‘General Principles for the
Development of Vaccines to
Protect against Global
Infectious Diseases’’
To address the gap in regulatory
pathways for global vaccines, the FDA’s
new guidance document provides an
additional solution by indicating that (1)
the FDA can license vaccines to protect
against infectious diseases or conditions
not endemic in the US, (2) the regulatory
pathway is the same as for vaccines
licensed for use in the US, and (3) the
clinical data from trials conducted outside
the US can be used for licensure. The
principles in this document are supported
by legislation, including the Food and
Drug Administration Amendments Act of
2007 section 524, which recognizes the
importance of accelerating the develop-
ment of products that prevent diseases for
which there is no market in the US. The
document is an important declaration, for
it ensures that a vaccine for a disease not
endemic to the US can be considered for
licensure if it has been shown to be safe
and effective under the FDA’s Investiga-
tional New Drug process. The Investiga-
tional New Drug process is particularly
thorough in that it provides the vaccine
sponsor with a complete review of (1) the
purity of the product and (2) the nonclin-
ical data, which ensures that the product is
manufactured correctly each time. It also
uses an independent analysis of the clinical
trial results, which, along with the review
by an FDA Advisory Board of experts,
provides reliable advice on the safety and
effectiveness of the new vaccine. Licensure
by the FDA provides a strong foundation
for countries that lack well-resourced
regulatory agencies to consider this new
vaccine for registration in their countries.
As mentioned, it also facilitates WHO’s
ability to approve this new vaccine for
global distribution through its vaccine
prequalification and procurement process.
The new FDA guidance also points out
that vaccines for global diseases may meet
the requirements for ‘‘accelerated approv-
al,’’ which can significantly shorten the
timelines for licensure in the US, or for
designation as an ‘‘orphan drug,’’ which
provides for a waiver of FDA user fees
usually required for vaccine licensure.
To be precise, the FDA has, in the past,
licensed vaccines for which there was
limited disease in the US, in particular
typhoid vaccine and Japanese encephalitis
vaccine, although both of these vaccines
were targeted in part for US military
personnel and for US citizens traveling
abroad [12,13]. The new guidance reaf-
firms the FDA’s ability to use foreign
clinical data for licensure, as used in the
examples above and also for the licensure
of acellular pertussis vaccines for children
in the US [14]. The recent licensure by the
FDA of H5N1 influenza virus vaccine for
the pandemic flu stockpile, for which no
large efficacy trial was possible and little
disease incidence exists, may also have
helped provide a rationale for licensing a
vaccine not endemic to the US.
Issues, Challenges, and
Implementation
It is clear, however, that the success of
this promising FDA initiative will depend
both upon the vaccine developers’ willing-
ness to submit their products to the
rigorous FDA review process and on the
FDA’s ability to effectively implement the
new recommendations. There are likely to
be significant challenges for FDA review-
ers. Although even a partially effective
vaccine can have a major impact on
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traditionally not licensed vaccines with
efficacy below 80%. The guidance docu-
ment does not describe the principles FDA
will use to license a vaccine that has
efficacy levels unlikely to be accepted in
the US but determined to be at a level that
would save hundreds of thousands of lives
annually in a country or a region where
the disease is epidemic. Other questions
are raised by the document. For example,
how would a malaria vaccine for children
be labeled for use if there is no US target
population? Will developing countries be
concerned that CBER/FDA could poten-
tially use a different standard for review of
products that will only rarely be used in
the US? Will the cash-strapped FDA be
given the resources to implement this new
mandate? And finally, since this document
addresses vaccines specifically, are similar
licensing guidelines followed for drugs,
therapeutics, and diagnostics?
Together with the new ‘‘priority review
voucher’’ for tropical diseases, another
program recently instituted by the US
FDA to interest sponsors in developing
products for tropical diseases (see Box 2),
this new guidance offers paths for devel-
opers of vaccines for global diseases to
access the regulatory experience and
strengths of the US FDA. These new
approaches are untested, and further
public forums and continued surveillance
as they are implemented should be
encouraged to evaluate their contribution
to global health. Nevertheless, the US
FDA has given global vaccine developers
some rules to play by, and the willingness
of the FDA to engage in this global
enterprise should be applauded.
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Box 2. Tropical Disease Priority Review Voucher
Passage of the Food and Drug Administration Amendments Act of 2007 added
section 524 to the Federal Food, Drug, and Cosmetic Act, which authorizes the
FDA to award priority review vouchers to sponsors developing certain tropical
disease products [15]. Products on the current list include: tuberculosis, malaria,
blinding trachoma, Buruli ulcer, cholera, dengue, dracunculiasis, fascioliasis,
trypanosomiasis, leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis,
schistosomiasis, helminthiasis, and yaws. Upon licensure of the product for the
tropical disease, a voucher is issued to the sponsor that can be used to obtain a
priority review for any vaccine or drug. Under ‘‘priority review status,’’ the FDA
commits to the goal to review and approve (or provide a complete response
letter to) an application no later than six months following receipt of the
submission. This is advantageous for the manufacturer since it could translate
into several months of market exclusivity and profit. In addition, vouchers can be
transferred to another sponsor, which provides an opportunity for selling or
trading the vouchers.
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